Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

IMUX

Immunic Inc

Apr 18 • 04:00PM ET

1.27

Dollar change +0.06
Percentage change 4.96	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI IWC AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.11	Insider Own	7.53%	Shs Outstand	89.93M	Perf Week	-9.29%
Market Cap	114.21M	Forward P/E	-	EPS next Y	-0.99	Insider Trans	0.00%	Shs Float	83.16M	Perf Month	-3.79%
Income	-93.61M	PEG	-	EPS next Q	-0.26	Inst Own	21.04%	Short Float	3.64%	Perf Quarter	6.72%
Sales	0.00M	P/S	-	EPS this Y	53.18%	Inst Trans	-2.58%	Short Ratio	4.73	Perf Half Y	-3.79%
Book/sh	0.64	P/B	1.98	EPS next Y	-0.54%	ROA	-102.84%	Short Interest	3.03M	Perf Year	-21.60%
Cash/sh	0.52	P/C	2.45	EPS next 5Y	15.50%	ROE	-131.28%	52W Range	0.95 - 3.11	Perf YTD	-15.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	31.12%	ROI	-316.58%	52W High	-59.16%	Beta	1.94
Dividend TTM	-	Quick Ratio	2.12	Sales past 5Y	0.00%	Gross Margin	-	52W Low	34.38%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	2.12	EPS Y/Y TTM	44.20%	Oper. Margin	0.00%	RSI (14)	46.36	Volatility	8.47% 6.92%
Employees	77	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	11.50
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	70.32%	Payout	-	Rel Volume	0.44	Prev Close	1.21
Sales Surprise	-	EPS Surprise	6.34%	Sales Q/Q	-	Earnings	Feb 22 BMO	Avg Volume	640.44K	Price	1.27
SMA20	-2.91%	SMA50	-4.17%	SMA200	-13.73%	Trades		Volume	280,158	Change	4.96%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Sep-19-22	Resumed	H.C. Wainwright	Buy	$26
Apr-15-21	Initiated	Aegis Capital	Buy	$55
Mar-24-21	Initiated	JMP Securities	Mkt Outperform	$55
Oct-02-20	Initiated	SVB Leerink	Outperform	$45
Aug-26-20	Initiated	Piper Sandler	Overweight	$71
Aug-07-20	Resumed	ROTH Capital	Buy	$64
Jul-20-20	Initiated	BMO Capital Markets	Outperform	$40
Jun-05-20	Initiated	Wedbush	Outperform	$59
May-11-20	Initiated	H.C. Wainwright	Buy	$45
Mar-25-20	Initiated	ROTH Capital	Buy	$44
Jul-11-19	Initiated	Chardan Capital Markets	Buy	$40

Show Previous Ratings

Apr-04-24 06:30AM	Immunic to Host MS R&D Day and Participate in Investor Conferences in April (PR Newswire)
Mar-21-24 12:14PM	Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month (News Direct)
11:37AM	Immunic secures key patent, boosting MS drug exclusivity and global IP strategy (News Direct)
Mar-20-24 06:30AM	Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States (PR Newswire)
Mar-08-24 06:53AM	Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024 (News Direct)
06:30AM	Loading…
Mar-07-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in March (PR Newswire)
Feb-29-24 06:30AM	Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 (PR Newswire)
Feb-23-24 09:02PM	Immunic Inc (IMUX) Reports Year-End 2023 Financial Results (GuruFocus.com)
11:04AM	Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 10:59AM	Immunic reports successful 2023 and prepares for key 2025 milestones (News Direct)
06:30AM	Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update (PR Newswire)
Feb-15-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update (PR Newswire)
Feb-01-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in February (PR Newswire)
Jan-05-24 06:35AM	Immunic Highlights 2023 Accomplishments and Upcoming Milestones (PR Newswire)
06:30AM	Immunic, Inc. Announces Private Placement of up to $240 Million (PR Newswire)
06:30AM	Loading…
Nov-21-23 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis (PR Newswire)
Nov-14-23 01:25PM	Immunic focusing on business development during Q4 (News Direct)
06:36AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 06:30AM	Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update (PR Newswire)
Nov-02-23 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts (PR Newswire)
Oct-26-23 06:30AM	Immunic to Participate in Scientific and Industry Conferences in November (PR Newswire)
Oct-24-23 07:51AM	Immunic CSO hails "great" progress with MS program (News Direct)
Oct-16-23 06:30AM	Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 (PR Newswire)
Oct-15-23 06:30AM	Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 (PR Newswire)
Oct-11-23 06:30AM	Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting (PR Newswire)
05:15AM	Immunic "super excited" about latest PMS trial data (News Direct)
Oct-10-23 09:07AM	Immunic's investors appeased by interim biomarker data from phase 2 MS trial (FierceBiotech.com) -13.84%
Oct-09-23 04:01PM	Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
Oct-04-23 06:30AM	Immunic to Participate in Scientific Conferences in October (PR Newswire)
06:30AM	Loading…
Sep-06-23 06:30AM	Immunic to Participate in Industry and Investor Conferences in September (PR Newswire)
Aug-21-23 08:00AM	Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment (News Direct)
Aug-17-23 06:30AM	Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
Aug-07-23 09:50AM	Immunic CEO says Q2 results "couldn't be better" (News Direct) -5.97%
Aug-03-23 06:47AM	Immunic: Q2 Earnings Snapshot (AP Finance)
06:30AM	Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Aug-01-23 06:30AM	Immunic to Participate in Investor and Scientific Conferences in August (PR Newswire)
Jul-28-23 04:19PM	10 Best Rated Penny Stocks to Buy According to Analysts (Insider Monkey) +16.18%
Jul-27-23 06:30AM	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update (PR Newswire) -6.42%
Jul-25-23 08:00AM	Immunic Inc eyeing "big step" for multiple sclerosis patients (News Direct)
Jul-24-23 10:33AM	With 50% stake, Immunic, Inc. (NASDAQ:IMUX) seems to have captured institutional investors' interest (Simply Wall St.)
Jun-29-23 06:30AM	Immunic to Participate in Scientific and Investor Conferences in July (PR Newswire) +18.56%
Jun-27-23 09:56AM	These 2 Strong Buy Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler (TipRanks) +11.89%
09:11AM	Pleasing Signs As A Number Of Insiders Buy Immunic Stock (Simply Wall St.)
Jun-26-23 03:44PM	Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases (News Direct)
May-31-23 07:42AM	Immunic ultimately hoping to "offer patients a new kind of treatment" for multiple sclerosis (News Direct) -5.17%
May-30-23 06:30AM	Immunic to Participate in Scientific and Investor Conferences in June (PR Newswire)
May-17-23 10:00AM	Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program (News Direct) +6.47%
06:30AM	Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis (PR Newswire)
May-16-23 01:07PM	Immunic Inc set to bring relief with encouraging results (News Direct)
May-11-23 06:40AM	Immunic: Q1 Earnings Snapshot (AP Finance)
06:30AM	Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-09-23 06:30AM	Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update (PR Newswire)
May-06-23 06:30AM	Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action (PR Newswire)
May-04-23 06:30AM	Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders (PR Newswire) -5.78%
Apr-27-23 06:30AM	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. (PR Newswire)
Apr-26-23 06:30AM	Immunic to Participate in Investor and Scientific Conferences in May (PR Newswire)
Apr-13-23 08:00AM	Immunic gets a "positive surprise" from lead asset trial (News Direct) +10.14%
Apr-06-23 02:10PM	Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data (Zacks) -10.32%
Apr-05-23 12:30PM	After Positive Data In Ulcerative Colitis Study, Immunic Prioritizes Vidofludimus Calcium Program With One More Candidate (Benzinga) +6.16%
06:30AM	Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis (PR Newswire)
Mar-02-23 06:30AM	Immunic to Participate in Investor and Scientific Conferences in March (PR Newswire)
Feb-28-23 05:22AM	Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-26-23 08:23AM	Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-23-23 06:30AM	Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update (PR Newswire)
Feb-22-23 06:30AM	Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 (PR Newswire)
Feb-16-23 06:30AM	Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update (PR Newswire) -6.60%
Feb-09-23 06:30AM	Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need (PR Newswire) -9.38%
Jan-25-23 06:30AM	Immunic to Participate in Scientific and Investor Conferences in February (PR Newswire)
Jan-18-23 06:31AM	Quite a few insiders invested in Immunic, Inc. (NASDAQ:IMUX) last year which is positive news for shareholders (Simply Wall St.)
Nov-17-22 08:04AM	Immunic Touts Positive Vidofludimus Calcium Data In Multiple Sclerosis Candidate (Benzinga)
06:30AM	Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential (PR Newswire)
Nov-10-22 06:30AM	Immunic to Participate in Investor and Scientific Conferences in November and December (PR Newswire)
Nov-03-22 06:30AM	Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) -7.60%
Oct-27-22 06:30AM	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update (PR Newswire)
Oct-21-22 03:14PM	Analyst Downgrades Immunic After Lack of Details Drive Uncertainty (Benzinga) -77.39%
06:52AM	Immunic's Early Cut Data From Psoriasis Candidate Failed To Show Desired Activity Signal Over Placebo (Benzinga)
Oct-20-22 04:01PM	Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate (PR Newswire)
Oct-10-22 07:00AM	Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing (PR Newswire) +56.57%
Oct-04-22 06:30AM	Immunic to Participate in Scientific and Industry Conferences in October (PR Newswire) +12.97%
Sep-20-22 01:39PM	Immunic Says Potential Inflammatory Disease Candidate Is Safe, Tolerable In Healthy Participants (Benzinga) -11.69%
06:30AM	Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects (PR Newswire)
Sep-19-22 03:03PM	Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger (Benzinga)
Sep-16-22 10:11AM	Immunic, Inc.'s (NASDAQ:IMUX) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures (Simply Wall St.)
Sep-01-22 06:30AM	Immunic, Inc. to Participate in Investor Conferences in September (PR Newswire)
Aug-16-22 06:30AM	Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium (PR Newswire) -7.29%
Aug-04-22 06:30AM	Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) +23.14%
Aug-02-22 06:30AM	Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference (PR Newswire)
Jul-28-22 06:30AM	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update (PR Newswire)
Jul-18-22 09:04AM	Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky (Simply Wall St.)
Jul-07-22 12:00PM	Immunic (IMUX) Moves to Buy: Rationale Behind the Upgrade (Zacks) +5.40%
Jul-06-22 06:30AM	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén (PR Newswire)
Jun-28-22 06:30AM	Immunic to Participate in Industry and Scientific Conferences in July (PR Newswire)
Jun-15-22 06:30AM	Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology (PR Newswire) +5.26%
Jun-08-22 06:30AM	Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June (PR Newswire) +5.26%
Jun-03-22 10:51AM	Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails (Zacks) +7.96%
Jun-02-22 06:30AM	Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update (PR Newswire) -46.78%
May-15-22 08:38AM	Duane Nash Is The Executive Chairman of Immunic, Inc. (NASDAQ:IMUX) And They Just Picked Up 166% More Shares (Simply Wall St.)
May-10-22 06:30AM	Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) +5.36%
May-05-22 06:30AM	Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease (PR Newswire) -9.43%

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Whaley Glenn	Chief Financial Officer	May 15 '23	Buy	1.75	5,000	8,750	25,510	May 16 08:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMUX

Immunic Inc

Upgrade your FINVIZ experience